Why OHI Stock advanced +0.30% Today — RQD Quant Desk Flash

Per the Roarable RQD rating, OHI scores 66 out of 100, a C+ grade labeled "Roarable Hold — Upper Neutral / Watch for Breakout." The five pillars break down as follows. Fundamental Cash Engine scores 14 of 20, with ROIC at 0% and an FCF yield of 5.81%, indicating that cash generation is strong relative to the share price while reported returns on invested capital are negligible. Whale 13F Flow scores 12 of 20, reflecting institutional accumulation and options positioning that is supportive but not dominant. Insider Conviction scores 13 of 20, based on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 12 of 20, with a beta of 1.08 and sector sensitivity that places the stock modestly more volatile than the market. Forensic Balance Sheet scores 15 of 20, the strongest pillar, supported by an Altman Z-Score of 2.5, a Piotroski F-Score of 9 of 9, and a Debt/Equity ratio of 0.5.

For a prospective investor evaluating the stock today, the upside drivers visible in these facts are the cash-flow yield, the clean forensic profile, and the stock's position near the upper portion of its 52-week range while the rating labels it as a candidate for a breakout. The principal valuation tradeoff is that the reported EV/EBITDA of 95 and the near-zero ROIC and margins sit uneasily against the dividend yield of 5.5% and the FCF yield; the investor must weigh whether reported cash flow reflects durable earnings power or is distorted by items that do not appear in the earnings line. The rating does not resolve this, and the verdict language should be read as an analytical classification, not a recommendation.

Omega Healthcare Investors Inc. (OHI) is a NYSE-listed issuer in the Financials sector, within the Real Estate Investment Trusts industry, per the company profile. The source data does not provide a description of its products, customers, or revenue model beyond sector and industry classification. Reported revenue of $1190.1M for FY 2025 per the SEC financials indicates a revenue base of meaningful scale, but the source data does not state how that revenue is generated.

Per the SEC financials, revenue grew from $949.7M in FY 2023 to $1190.1M in FY 2025, while reported operating income and net income remained below $1M in each period, consistent with the 0.1% operating and net margins in the market data and the 0% gross margin. Per the Roarable RQD rating, ROIC is 0%. The Altman Z-Score of 2.5 and Piotroski F-Score of 9 of 9 are reported in the forensic balance sheet pillar, and Debt/Equity is 0.5. Reported debt declined from $2325.2M in FY 2024 to $2073.9M in FY 2025, while cash fell from $518.3M to $27.0M over the same period.

Per the recent news feed, the headlines include a Yahoo Finance forecast report flagged as a market wire item, a Seeking Alpha report stating that OHI was raised to Buy-equivalent at Citizens after the stock cooled from a 52-week high (flagged as a green catalyst), a MarketScreener notice of a quarterly cash dividend payable on November 16, 2026, a MarketBeat research roundup, a TIKR.com comparison of OHI against VICI Properties on dividend yield, and a Yahoo Finance report that OHI transferred Florida facilities to PACS and incurred a $90 Million expense. The dividend notice and the rating upgrade are the most directly investor-relevant items. The Florida facility transfer and its $90 Million expense are a risk watch item, since the expense is material relative to reported operating income of $0.7M. Per the Butterfly Supply-Chain Graph, there are no supply-chain links and no proprietary signals.

• What is the explanation for the $90 Million expense associated with the Florida facility transfer, and how does it affect reported earnings and cash flow?
• Why does reported EV/EBITDA of 95 coexist with a 5.5% dividend yield and near-zero margins, and which earnings measure best reflects distributable cash?
• What is the composition of the reported debt and whether the decline from $2325.2M to $2073.9M reflects scheduled repayment or refinancing?
• What are the TTM and forward earnings per share, which are absent from the source data?
• What are the consensus analyst rating and price target, given that analyst data is unavailable?